Clinical Trials Resource Center

New Medical Therapies™

Head Lice

December 26, 2011

Hatchtech released results from a phase IIb trial of DeOvo topical treatment for head lice. This double blind, randomized trial, Ha02-003, enrolled 140 subjects, ages two years and older, with head lice infestation. The subjects received a single 10-minute treatment with DeOvo (0.74% w/v or 0.37% w/v) or placebo. The primary endpoint was the proportion of all subjects who are lice free at all follow-up visits through the Day 14 visit. The primary efficacy results demonstrated a statistically significant (p<0.001) and clinically relevant outcome in both the DeOvo treatment groups (85.7% and 67.4% treatment success in the high and low dose arm, respectively) compared to the placebo group (23.4% treatment success). No serious adverse events were reported.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.